title: Endogenous cholecystokinin plays a role in down-regulation of pancreatic amylase independent of dietary carbohydrate in rats.
abstract: The role of cholecystokinin (CCK) in the regulation of pancreatic amylase has not been fully clarified. We examined the effects of hyperCCKemia with chronic pancreatico-biliary diversion (PBD) and blockade of CCK(A)-receptor on rat pancreatic amylase activity and mRNA abundance. Also, we examined the relationship between diet and CCK in terms of regulation of pancreatic amylase. PBD was produced by transposition of the duodenal segment containing the ampulla of Vater to the upper ileum. A potent CCK(A)-receptor antagonist, devazepide, was injected (6 mg/kg body weight per day for 5 days) in the PBD rats fed with diets containing normal or low level of carbohydrate (695 or 345 g sucrose/kg diet). The specific activity and mRNA abundance of the pancreatic amylase were constantly lower 4, 10 and 28 days after PBD than those after the sham operation. Devazepide treatment completely restored the amylase activity lowered by PBD without any increases in amylase mRNA. Feeding a high-protein low-carbohydrate diet suppressed the pancreatic amylase activity and mRNA abundance in PBD rats to a similar degree in those treated, and those untreated, with devazepide. We conclude that endogenous CCK suppresses pancreatic amylase production, and we speculate that CCK reduced translational efficiency of amylase mRNA. The effect of CCK on amylase production is independent of regulation by dietary carbohydrate.
authors.affiliation: Division of Applied Bioscience, Graduate School of Agriculture, Hokkaido University Kita-9, Nishi-9, Kita-ku, 060-8589, Sapporo, Japan. hara@chem.agr.hokudai.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: S
authors.initials: S
authors.lastname: Ohyama
authors.forename: T
authors.initials: T
authors.lastname: Hira
mesh_terms: D000681:Amylases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000818:Animals; D015904:Biliopancreatic Diversion; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D020109:Devazepide / Q000008:administration & dosage; D004040:Dietary Carbohydrates / Q000008:administration & dosage*; D015536:Down-Regulation / Q000187:drug effects; D008297:Male; D010179:Pancreas / Q000201:enzymology* / Q000601:surgery; D051381:Rats; D017207:Rats, Sprague-Dawley; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D013395:Sucrose / Q000008:administration & dosage
chemical_list: D004040:Dietary Carbohydrates; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D013395:Sucrose; D002766:Cholecystokinin; D000681:Amylases; D020109:Devazepide